Chantal Parpex - Integragen Director, representing CDC Innovation
| ALINT Stock | EUR 0.54 0.01 1.89% |
Director
Dr. Chantal Parpex serves as Director at Integragen SA, representing CDC Innovation since October 25, 2011. She has over 20 years experience in the pharmaceutical industry . From 1985 to 1997, within the Rhone Poulenc Rorer group, she first held the position of Development Director at Laboratoires Specia, and then became Managing Director of the Rhone DPC Europe joint venture and Vice President Corporationrationrate Marketing for a range of therapeutic sectors. After having managed clinical and preclinical development for Servier, Dr. Parpex joined Gemini Consulting as Principal Consultant in 1999. In the year 2000, she created and managed Biogestion . She is Chairman and Member of the Management Board of CDC Innovation SAS. She joined CDC Entreprises Innovation in 2004. She holds a PhD Degree in Medicine, and a Diploma from the CedepINSEAD International General Management Program. since 2011.
| Tenure | 14 years |
| Professional Marks | Ph.D |
| Phone | 33 1 60 91 09 00 |
| Web | https://integragen.com |
Integragen Management Efficiency
The company has return on total asset (ROA) of 0.0149 % which means that it generated a profit of $0.0149 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1498 %, meaning that it generated $0.1498 on every $100 dollars invested by stockholders. Integragen's management efficiency ratios could be used to measure how well Integragen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 7 records | DIRECTOR Age | ||
| Sarah Gould | Adocia | N/A | |
| Laurent Arthaud | Adocia | 56 | |
| Remi Soula | Adocia | N/A | |
| Valerie Danaguezian | Adocia | N/A | |
| YouPing Chan | Adocia | N/A | |
| Ekaterina Smirnyagina | Adocia | 52 | |
| Geraldine Soula | Adocia | N/A | |
Management Performance
| Return On Equity | 0.15 | |||
| Return On Asset | 0.0149 |
Integragen Leadership Team
Elected by the shareholders, the Integragen's board of directors comprises two types of representatives: Integragen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Integragen. The board's role is to monitor Integragen's management team and ensure that shareholders' interests are well served. Integragen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Integragen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA DVM, CEO Director | ||
| Joerg Leenings, Head Centre | ||
| JeanPol Detiffe, Chief Director | ||
| Francois Liebaert, Vice President - Research & Development and Medical Affairs | ||
| Emmanuel Martin, Director Sales & Marketing for the Services Business Unit | ||
| Gerald Wagner, Director | ||
| Brengre Gnin, Research Academics | ||
| Laurence Lamotte, Director of Administration and Finance | ||
| Anne Philippi, CoFounder Epidemiology | ||
| Benoit Adelus, Director | ||
| Bernard Courtieu, Chairman of the Board, Chief Executive Officer | ||
| Philippe Boucheron, Director, representing CDC Entreprises | ||
| Francis Rousseau, Director of Genomics | ||
| Chantal Parpex, Director, representing CDC Innovation | ||
| Louis Nisbet, Director, representing Kurma Life Sciences Partners | ||
| Pierre Flamant, Adm Director | ||
| Cyril Harfouche, Director | ||
| Larry Yost, Chief Executive Officer - Integragen Inc |
Integragen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Integragen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | |||
| Return On Asset | 0.0149 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 5.39 M | |||
| Shares Outstanding | 6.6 M | |||
| Shares Owned By Insiders | 65.89 % | |||
| Price To Earning | 44.59 X | |||
| Price To Book | 3.91 X | |||
| Price To Sales | 0.63 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Integragen Stock Analysis
When running Integragen's price analysis, check to measure Integragen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integragen is operating at the current time. Most of Integragen's value examination focuses on studying past and present price action to predict the probability of Integragen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integragen's price. Additionally, you may evaluate how the addition of Integragen to your portfolios can decrease your overall portfolio volatility.